Detailed Information

Cited 0 time in webofscience Cited 2 time in scopus
Metadata Downloads

Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea

Authors
Jeong, Y. J.Kim, H.Baik, S. J.Kim, T. M.Yang, S. J.Lee, S. -H.Cho, J. -H.Lee, H.Yim, H. W.Choi, I. Y.Yoon, K. -H.Kim, H. -S.
Issue Date
Jun-2017
Publisher
WILEY
Keywords
cost-effectiveness; HMG-CoA reductase inhibitor; statin
Citation
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.42, no.3, pp 292 - 300
Pages
9
Journal Title
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume
42
Number
3
Start Page
292
End Page
300
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/2376
DOI
10.1111/jcpt.12512
ISSN
0269-4727
1365-2710
Abstract
What is known and objectiveThere are a few Korean studies on the economics of statins based on reduction in low-density lipoprotein cholesterol (LDL-C) data from other countries. This study aimed to analyse and compare the cost-effectiveness of statins according to the baseline LDL-C level in Korea. MethodsBetween January 2009 and December 2015, the data of patients who were prescribed statins for the first time were extracted from electronic medical records. We performed a cost-effectiveness analysis (CEA) based on the LDL-C reduction rate (CEA-RR) and target achievement rate. Results and discussionAmong high-intensity statins, the CEA-RR value of rosuvastatin (20 mg) was significantly lower than that of atorvastatin (40 mg) at all baseline LDL-C levels, except levels of 160-189 mg/dL. Additionally, at baseline LDL-C levels of 130-159 mg/dL, the CEA-RR value of rosuvastatin (20 mg) was three times lower than that of atorvastatin (40 mg) (91 25 $/% vs. 317 +/- 150 $/%, P < 0001). Among moderate-to-low-intensity statins, rosuvastatin (5 mg) showed the lowest CEA-RR value (40 +/- 06 $/%), and the value significantly increased for pitavastatin (2 mg) (80 +/- 06 $/%), atorvastatin (10 mg) (95 +/- 05 $/%), simvastatin (108 +/- 11 $/%) and pravastatin (40 mg) (115 +/- 09 $/%) in order (P < 00001). On changing from atorvastatin (10 mg) to atorvastatin (20 mg), the additional yearly cost was 160 and additional CEA-RR value was 274 $/%. On the other hand, on changing from atorvastatin (10 mg) to rosuvastatin (10 mg), the additional yearly cost was -163 and additional CEA-RR value was -18 $/%. What is new and conclusionWe successfully compared the cost-effectiveness of statins according to the baseline LDL-C level in Korea. It is expected that our findings will help clinical decision-making with regard to statin prescription, and this will help reduce national medical expenditure.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyun Ah photo

Kim, Hyun Ah
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE